Rosiglitazone May Improve Beta-Cell Function in Type 2 Diabetes

Rosiglitazone improves pancreatic ?-cell function in type 2 diabetes mellitus (DM) independent of correction of glucotoxicity, according to the results of a randomized trial published in the November issue of Diabetes Care.